We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock
ONCT

Delisted

ONCT was delisted on the 2nd of December, 2024.

Back to rankings

52 hedge funds and large institutions have $3.26M invested in Oncternal Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less funds holding

Funds holding: 54 → 52 (-2)

18% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 11

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

58% less capital invested

Capital invested by funds: $7.86M → $3.26M (-$4.6M)

Holders
52
Holders Change
-2
Holders Change %
-3.7%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
9
Reduced
11
Closed
7
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
-$3K

Top Buyers

Rank Fund Capital Flow
1
RB
Richmond Brothers
Michigan
+$83.3K
2
Millennium Management
Millennium Management
New York
+$49.2K
3
Renaissance Technologies
Renaissance Technologies
New York
+$10.5K
4
Morgan Stanley
Morgan Stanley
New York
+$10.4K
5
BWP
Balboa Wealth Partners
Arizona
+$9.89K

Top Sellers

Rank Fund Capital Flow
1
BC
BIT Capital
Germany
-$566K
2
BlackRock
BlackRock
New York
-$41.4K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$35.4K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$19K
5
CWA
CM Wealth Advisors
Ohio
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$987K -$1.07K -162 -0.1%
Millennium Management
2
Millennium Management
New York
$567K +$49.2K +7,467 +10%
BlackRock
3
BlackRock
New York
$271K -$41.4K -6,273 -14%
KCM
4
Kennedy Capital Management
Missouri
$203K – – –
QPW
5
Quantum Private Wealth
Florida
$157K -$429 -65 -0.3%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$143K – – –
BJL
7
Brighton Jones LLC
Washington
$117K +$1.01K +153 +0.9%
RB
8
Richmond Brothers
Michigan
$100K +$83.3K +12,634 +659%
Renaissance Technologies
9
Renaissance Technologies
New York
$99K +$10.5K +1,595 +13%
LPL Financial
10
LPL Financial
California
$59.2K – – –
State Street
11
State Street
Massachusetts
$55.7K – – –
IC
12
IEQ Capital
California
$49.8K – – –
Two Sigma Advisers
13
Two Sigma Advisers
New York
$44.1K -$594 -90 -1%
Corient Private Wealth
14
Corient Private Wealth
Florida
$42.8K -$8.66K -1,313 -17%
Acadian Asset Management
15
Acadian Asset Management
Massachusetts
$36K -$19K -2,883 -35%
Morgan Stanley
16
Morgan Stanley
New York
$33.8K +$10.4K +1,580 +48%
Northern Trust
17
Northern Trust
Illinois
$29.2K – – –
Two Sigma Investments
18
Two Sigma Investments
New York
$28.1K – – –
AWM
19
Axxcess Wealth Management
California
$24.3K – – –
Mercer Global Advisors
20
Mercer Global Advisors
Colorado
$19K -$264 -40 -1%
Envestnet Asset Management
21
Envestnet Asset Management
Illinois
$18.6K – – –
ROTUOC
22
Regents of the University of California
California
$18.5K – – –
BWP
23
Balboa Wealth Partners
Arizona
$16.4K +$9.89K +1,500 +171%
Creative Planning
24
Creative Planning
Kansas
$13.6K – – –
WCA
25
Waypoint Capital Advisors
Minnesota
$13.4K – – –
1
2 3

ONCT Hedge Fund Activity: Q2 2023 in Review

52 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q2 2023, worth a combined $3.26M — down 58% from $7.86M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ONCT and 5 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 9 added.

The largest buyer was Richmond Brothers, adding an estimated $83.3K. The largest seller was BIT Capital, exiting entirely with an estimated $566K sold.

  • 52 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q2 2023, down from 54 in Q1 2023.
  • Funds reported $3.26M of Oncternal Therapeutics, Inc. Common Stock stock for Q2 2023, down 58% quarter-over-quarter.
  • 5 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q2 2023 and 7 closed out, a net change of -2 holders.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q2 2023 was Richmond Brothers, an estimated $83.3K added.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q2 2023 was BIT Capital, an estimated $566K sold.

Based on aggregated 13F filings for Q2 2023.